CNBX RCC-33

**CNBX RCC-33** is a proprietary, non-psychoactive cannabinoid-based antitumor formulation being developed by Cannabics Pharmaceuticals for colorectal cancer. The formulation has been evaluated in preclinical colorectal cancer cell-line, human-biopsy, and mouse xenograft studies; the company has reported synergistic antitumor activity and tumor-growth/survival findings in these models. Its specific active cannabinoid composition, direct molecular targets, and precise mechanism of action have not been publicly disclosed. Cannabics has described the program as preclinical and has pursued preparation for a US FDA pre-IND interaction and prospective Phase I/IIa development. ([cnbxpharma.com](https://cnbxpharma.com/))